Skip to main content

Eli Lilly and Company Cardiometabolic Health revenue

  • LLY · NYSE
  • Pharmaceuticals
  • S&P 500
$1443.50+1.14%Close 13 Nov 2026 · Market value $1.36T

Cardiometabolic Health revenue at Eli Lilly and Company came to $12.4B for the quarter to 30 Sep 2026, up 39.6% from a year earlier.

As Eli Lilly and Company reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2026.

By quarter

$4.5BDec 2023$4.1BMar 2024$5.7BJun 2024$5.5BSep 2024$6.5BDec 2024$6.6BMar 2025$8.4BJun 2025$8.9BSep 2025$10.1BDec 2025$9.9BMar 2026$11.7BJun 2026$12.4BSep 2026
Eli Lilly and Company Cardiometabolic Health revenue, every reported period
Period endingCardiometabolic Health revenueChange on a yearFiled
30 Sep 2026$12.4Bup 39.6%29 Oct 2026
30 Jun 2026$11.7Bup 40.4%5 Aug 2026
31 Mar 2026$9.9Bup 50.9%30 Apr 2026
31 Dec 2025$10.1Bup 54.1%12 Feb 2026
30 Sep 2025$8.9Bup 60.7%30 Oct 2025
30 Jun 2025$8.4Bup 46.3%7 Aug 2025
31 Mar 2025$6.6Bup 60.8%1 May 2025
31 Dec 2024$6.5Bup 46.2%19 Feb 2025
30 Sep 2024$5.5Bup 59.5%30 Oct 2024
30 Jun 2024$5.7Bup 51.2%8 Aug 2024
31 Mar 2024$4.1Bup 33.0%30 Apr 2024
31 Dec 2023$4.5Bup 56.4%21 Feb 2024
30 Sep 2023$3.5Bup 39.0%2 Nov 2023
30 Jun 2023$3.8Bup 65.0%8 Aug 2023
31 Mar 2023$3.1Bup 35.1%27 Apr 2023
31 Dec 2022$2.9Bup 17.2%22 Feb 2023
30 Sep 2022$2.5Bup 16.1%1 Nov 2022
30 Jun 2022$2.3Bup 10.2%4 Aug 2022
31 Mar 2022$2.3Bup 10.5%29 Apr 2022
31 Dec 2021$2.4Bup 8.4%23 Feb 2022
30 Sep 2021$2.1Bup 19.2%27 Oct 2021
30 Jun 2021$2.1Bup 11.0%3 Aug 2021
31 Mar 2021$2.1Bup 3.5%30 Apr 2021
31 Dec 2020$2.2Bup 4.8%17 Feb 2021
30 Sep 2020$1.8Bup 0.8%28 Oct 2020
30 Jun 2020$1.9Bdown 0.5%31 Jul 2020
31 Mar 2020$2.0Bup 15.8%1 May 2020
31 Dec 2019$2.1B—19 Feb 2020
30 Sep 2019$1.8B—25 Oct 2019
30 Jun 2019$1.9B—2 Aug 2019
31 Mar 2019$1.7B—2 May 2019

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Eli Lilly and Company: Zepbound revenue · Mounjaro revenue · Oncology revenue · Verzenio revenue · Immunology revenue · Jardiance revenue · Trulicity revenue · Taltz revenue · Neuroscience revenue · United States revenue · Outside U.S. revenue · Europe revenue · Rest of world revenue · China revenue · Japan revenue · financial statements

Every KPI and segment of LLY, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.